As previously projected, the Scottish Medicines Consortium has now approved the clinical use of abiraterone acetate, making the drug available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after failure of treatment with docetaxel-based chemotherapy throughout the United Kingdom.
Filed under: Drugs in development, Management, Treatment Tagged: | abiraterone, Scotland
Search for new and
ongoing trials on the
CTAG PCa web site
